Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Study of Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Research Question:
Do the drugs olaparib and abiraterone safe and effective to treat men who have metastatic castration-resistant prostate cancer?

Basic Study Information

Purpose:
This study will determine if the drugs olaprib and abiraterone are safe, well-tolerated and effective in treating metastatic castration-resistant prostate cancer. Metastatic castration-resistant prostate cancer is when the cancer has spread to parts of the body other than the prostate, and it is able to grow and spread even though drugs or other treatments to lower the amount of male sex hormones are being used to manage the cancer. Patients cannot have received prior chemotherapy or new hormonal agents metastatic castration-resistant prostate cancer. Approximately 720 patients globally will be randomized to treatment with either olaparib and abiraterone or placebo and abiraterone.

Location: University of Rochester Medical Center
Study Reference #: ULEU18130

Lead Researcher (Principal Investigator)

Lead Researcher:  Eric Huselton

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485
Email: Haley_Misch@URMC.Rochester.edu

Additional Study Details

Return to Search